Caxton Corp Takes $12.43 Million Position in Kala Pharmaceuticals Inc (KALA)
Caxton Corp acquired a new position in shares of Kala Pharmaceuticals Inc (NASDAQ:KALA) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 544,220 shares of the company’s stock, valued at approximately $12,430,000. Kala Pharmaceuticals accounts for approximately 12.7% of Caxton Corp’s holdings, making the stock its 2nd largest holding. Caxton Corp owned about 2.22% of Kala Pharmaceuticals at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently bought and sold shares of KALA. Teachers Retirement System of The State of Kentucky bought a new stake in shares of Kala Pharmaceuticals in the 3rd quarter valued at approximately $105,000. American International Group Inc. bought a new stake in shares of Kala Pharmaceuticals in the 3rd quarter valued at approximately $122,000. California State Teachers Retirement System bought a new stake in shares of Kala Pharmaceuticals in the 3rd quarter valued at approximately $301,000. Schwab Charles Investment Management Inc. bought a new stake in shares of Kala Pharmaceuticals in the 3rd quarter valued at approximately $313,000. Finally, Commonwealth Equity Services Inc bought a new stake in shares of Kala Pharmaceuticals in the 3rd quarter valued at approximately $360,000. Hedge funds and other institutional investors own 62.96% of the company’s stock.
Shares of Kala Pharmaceuticals Inc (NASDAQ KALA) opened at $17.53 on Thursday. Kala Pharmaceuticals Inc has a 12-month low of $13.51 and a 12-month high of $26.75. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.00 and a current ratio of 11.00.
Several brokerages recently commented on KALA. Wedbush reissued a “buy” rating and issued a $46.00 price target on shares of Kala Pharmaceuticals in a research note on Thursday, November 30th. J P Morgan Chase & Co set a $35.00 target price on Kala Pharmaceuticals and gave the stock a “buy” rating in a research report on Sunday, November 19th. Zacks Investment Research cut Kala Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 17th. Oppenheimer started coverage on Kala Pharmaceuticals in a research report on Tuesday, August 15th. They set an “outperform” rating and a $46.00 target price for the company. Finally, Bank of America started coverage on Kala Pharmaceuticals in a research report on Monday, August 14th. They issued a “buy” rating and a $33.00 price objective for the company. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $36.80.
WARNING: “Caxton Corp Takes $12.43 Million Position in Kala Pharmaceuticals Inc (KALA)” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/12/07/caxton-corp-takes-12-43-million-position-in-kala-pharmaceuticals-inc-kala.html.
Kala Pharmaceuticals Profile
Kala Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program.
Want to see what other hedge funds are holding KALA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kala Pharmaceuticals Inc (NASDAQ:KALA).
Receive News & Ratings for Kala Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.